Sang Kim is a Dermatology physician. ClinicalTrials.gov lists 48 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
761 Main Ave
Suite 102
Norwalk, CT 06851
Telephone
203-810-4151Registry record last updated 1 Feb 2017.
Clinical trials
- Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response
Sponsor: Korea University Guro Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20252 payments
- ABBVIE INC.Program year20251 payment
- Lilly USA, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
30.8%Azole Antifungal9.3%Ketoconazole100%Part D≥22 patientsTetracycline-class Drug9.3%Doxycycline Hyclate100%Part D≥15 patients+ 2 more classes in this area
Dermatology
24.4%Corticosteroid13.9%Triamcinolone Acetonide100%Part D≥51 patientsInterleukin-4 Receptor alpha Antagonist4.8%Dupixent Pen100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
15.2%Porphyrin Precursor4.8%Aminolevulinic acid hcl100%Part B, office-administered≥17 patientsNucleoside Metabolic Inhibitor4.6%Fluorouracil100%Part D≥19 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy
Yale University
FY2025$173,556K08AR079587 - Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy
Yale University
FY2024$173,556K08AR079587 - Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy
Yale University
FY2024$1,000K08AR079587
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”